The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC).
Vera Hirsh
Consultant or Advisory Role - Pfizer
Fiona Helen Blackhall
Consultant or Advisory Role - Lilly (U); Pfizer (U)
Honoraria - Lilly; Pfizer
Research Funding - Lilly; Pfizer
Expert Testimony - Pfizer (U)
Other Remuneration - Lilly; Pfizer
Dong-Wan Kim
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Benjamin Besse
Consultant or Advisory Role - Pfizer (U)
Research Funding - Pfizer
Hiroshi Nokihara
No relevant relationships to disclose
Ji-Youn Han
No relevant relationships to disclose
Vanessa Roberts Tassell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Arlene Reisman
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Shrividya Iyer
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Alice Tsang Shaw
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer